RITZ Venture Capital

Ritz Venture Capital, established in 2020 and based in Singapore, focuses on investing in early-stage technology companies. The firm aims to support STEM talents and foster innovation for a sustainable future. Its investment strategy encompasses various sectors, including food, healthcare, mobility, and digitalization, reflecting a commitment to nurturing advancements that can contribute to long-term societal benefits.

Sang Bin Ong

Managing Director

3 past transactions

UNIGRID

Series A in 2024
UNIGRID develops sustainable and affordable sodium-based batteries using abundant materials. They aim to put a battery into every home, the grid, and other distributed energy storage applications. They use dense Na-alloy and a non-flammable electrolyte, which led to high energy density and improved safety.

Knorex

Venture Round in 2023
Knorex is a B2B technology company, established in 2009, that focuses on simplifying digital marketing for businesses through its innovative programmatic advertising products and solutions. The company's flagship offering, Knorex XPO, is an AI-driven advertising management and execution cloud platform that integrates various advertising channels, including social media, search, video, audio, display, and digital out-of-home. By leveraging machine learning and artificial intelligence, Knorex XPO automates and optimizes marketing campaigns, enabling advertisers to deliver personalized messages to their target audiences effectively. Operating in the United States and the Asia-Pacific region, Knorex aims to democratize access to digital marketing, helping clients streamline their advertising processes and enhance performance.

ACM Biolabs

Venture Round in 2022
ACM Biolabs is a Singapore-based biotechnology company established in 2013 that specializes in developing innovative vaccines and antibodies using its proprietary artificial cell membrane (ACM) technology. This technology incorporates functional, folded membrane proteins into artificial cell membranes, stabilizing them and inducing a strong immune response. ACM Biolabs' approach has shown efficacy through both injected and oral administrations of synthesized membrane proteins. The company's pipeline includes a range of vaccines and antibodies for infectious diseases and personalized cancer treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.